Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Shares of Pacific Biosciences of California (PACB)   were down nearly 17% to $4.30 in premarket trading on Thursday. The Menlo Park, Calif.-based firm on Wednesday reported a first-quarter net loss of $23.9 million, versus $19.4 million in the same period last year. Product and service revenue rose 60% to $24.9 million.

Shares of Alexion Pharmaceuticals (ALXN) were up 3.2% to $124.60. The New Haven, Conn.-based firm on Thursday reported first-quarter non-GAAP diluted earnings per share of $1.38, compared to $0.99 in the year-ago period. Revenue was $870 million, up 24% year-over-year.

The company said revenue for the first quarter included a benefit of $29 million from a change in revenue recognition in 2017 for certain non-U.S. markets. Not counting the benefit of this accounting change, revenue was  $841 million, representing a  20% rise from the year-ago period.

For full-year 2017, Alexion raised its GAAP EPS guidance to $2.80 to $3.20 from the previous range of $2.55 to $3.05, and non-GAAP EPS guidance to $5.10 to $5.30 from the prior range of $5.00 to $5.25. The company reaffirmed its revenue guidance of $3.4 billion to $3.5 billion.

Other biotech stock movers include Arena Pharmaceuticals (ARNA) , up 4.3% to $1.45.

More from Health

Pros and Cons of Buying a Home With a Pool

Pros and Cons of Buying a Home With a Pool

Former First Lady Barbara Bush Dies at 92 Years Old

Former First Lady Barbara Bush Dies at 92 Years Old

Healthcare Enrollments Remain Steady in 2018

Healthcare Enrollments Remain Steady in 2018

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot